COVID-19 susceptibility and clinical outcomes in autoimmune inflammatory rheumatic diseases (AIRDs): a systematic review and meta-analysis.

Abstract

OBJECTIVE:

This meta-analysis aims to assess the susceptibility to and clinical outcomes of COVID-19 in autoimmune inflammatory rheumatic disease (AIRD) and following AIRD drug use.

MATERIALS AND METHODS:

We included observational and case-controlled studies assessing susceptibility and clinical outcomes of COVID-19 in patients with AIRD as well as the clinical outcomes of COVID-19 with or without use of steroids and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs).

RESULTS:

Meta-analysis including three studies showed that patients with AIRD are not more susceptible to COVID-19 compared to patients without AIRD or the general population (OR: 1.11, 95% CI: 0.58 to 2.14). Incidence of severe outcomes of COVID-19 (OR: 1.34, 95% CI: 0.76 to 2.35) and COVID-19 related death (OR: 1.21, 95% CI: 0.68 to 2.16) also did not show significant difference. The clinical outcomes of COVID-19 among AIRD patients with and without csDMARD or steroid showed that both use of steroid (OR: 1.69, 95% CI: 0.96 to 2.98) or csDMARD (OR: 1.35, 95% CI: 0.63 to 3.08) had no effect on clinical outcomes of COVID-19.

CONCLUSIONS:

AIRD does not increase susceptibility to COVID-19, not affecting the clinical outcome of COVID-19. Similarly, the use of steroids or csDMARDs for AIRD does not worsen the clinical outcome.

• Authors: J I Shin, S E Kim, M H Lee, M S Kim, S W Lee, S Park, Y H Shin, J W Yang, J M Song, S Y Moon, S Y Kim, Y Park, D I Suh, J M Yang, S H Cho, H Y Jin, S H Hong, H-H Won, A Kronbichler, A Koyanagi, L Jacob, J Hwang, K Tizaoui, K H Lee, J H Kim, D K Yon, L Smith
• Journal: European review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 26 Issue 10 Pg. 3760-3770 (05 2022) ISSN: 2284-0729 [Electronic] Italy
• PMID: 35647859 (Publication Type: Journal Article, Meta-Analysis, Systematic Review)

Chemical References

• Antirheumatic Agents

Topics

• Antirheumatic Agents (therapeutic use)
• Autoimmune Diseases
• Humans
• Incidence
• Rheumatic Diseases (drug therapy, epidemiology)
• COVID-19 Drug Treatment